A citation-based method for searching scientific literature

Luca Cantini, Raffit Hassan, Daniel H Sterman, Joachim G J V Aerts. Front Oncol 2020
Times Cited: 18







List of co-cited articles
90 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
Nicholas J Vogelzang, James J Rusthoven, James Symanowski, Claude Denham, E Kaukel, Pierre Ruffie, Ulrich Gatzemeier, Michael Boyer, Salih Emri, Christian Manegold,[...]. J Clin Oncol 2003
61

Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations.
Raphael Bueno, Eric W Stawiski, Leonard D Goldstein, Steffen Durinck, Assunta De Rienzo, Zora Modrusan, Florian Gnad, Thong T Nguyen, Bijay S Jaiswal, Lucian R Chirieac,[...]. Nat Genet 2016
382
50

Integrative Molecular Characterization of Malignant Pleural Mesothelioma.
Julija Hmeljak, Francisco Sanchez-Vega, Katherine A Hoadley, Juliann Shih, Chip Stewart, David Heiman, Patrick Tarpey, Ludmila Danilova, Esther Drill, Ewan A Gibb,[...]. Cancer Discov 2018
185
44

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Arnaud Scherpereel, Julien Mazieres, Laurent Greillier, Sylvie Lantuejoul, Pascal Dô, Olivier Bylicki, Isabelle Monnet, Romain Corre, Clarisse Audigier-Valette, Myriam Locatelli-Sanchez,[...]. Lancet Oncol 2019
157
33

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Gérard Zalcman, Julien Mazieres, Jacques Margery, Laurent Greillier, Clarisse Audigier-Valette, Denis Moro-Sibilot, Olivier Molinier, Romain Corre, Isabelle Monnet, Valérie Gounant,[...]. Lancet 2016
411
33

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Paul Baas, Arnaud Scherpereel, Anna K Nowak, Nobukazu Fujimoto, Solange Peters, Anne S Tsao, Aaron S Mansfield, Sanjay Popat, Thierry Jahan, Scott Antonia,[...]. Lancet 2021
54
33

Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
Maria J Disselhorst, Josine Quispel-Janssen, Ferry Lalezari, Kim Monkhorst, Jeltje F de Vries, Vincent van der Noort, Emmy Harms, Sjaak Burgers, Paul Baas. Lancet Respir Med 2019
85
27

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
Michele Maio, Arnaud Scherpereel, Luana Calabrò, Joachim Aerts, Susana Cedres Perez, Alessandra Bearz, Kristiaan Nackaerts, Dean A Fennell, Dariusz Kowalski, Anne S Tsao,[...]. Lancet Oncol 2017
189
27

Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
Evan W Alley, Juanita Lopez, Armando Santoro, Anne Morosky, Sanatan Saraf, Bilal Piperdi, Emilie van Brummelen. Lancet Oncol 2017
264
27

Novel insights into mesothelioma biology and implications for therapy.
Timothy A Yap, Joachim G Aerts, Sanjay Popat, Dean A Fennell. Nat Rev Cancer 2017
154
27

Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.
Guangwu Guo, Juliann Chmielecki, Chandra Goparaju, Adriana Heguy, Igor Dolgalev, Michele Carbone, Sara Seepo, Matthew Meyerson, Harvey I Pass. Cancer Res 2015
178
22

The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.
Matthew Bott, Marie Brevet, Barry S Taylor, Shigeki Shimizu, Tatsuo Ito, Lu Wang, Jenette Creaney, Richard A Lake, Maureen F Zakowski, Boris Reva,[...]. Nat Genet 2011
423
22


Novel therapies for malignant pleural mesothelioma.
Arnaud Scherpereel, Frederic Wallyn, Steven M Albelda, Camille Munck. Lancet Oncol 2018
66
22

Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
Aliya Noor Husain, Thomas V Colby, Nelson G Ordóñez, Timothy Craig Allen, Richard Luther Attanoos, Mary Beth Beasley, Kelly Jo Butnor, Lucian R Chirieac, Andrew M Churg, Sanja Dacic,[...]. Arch Pathol Lab Med 2018
218
16

EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach.
Andrew G Nicholson, Jennifer L Sauter, Anna K Nowak, Hedy L Kindler, Ritu R Gill, Martine Remy-Jardin, Samuel G Armato, Lynnette Fernandez-Cuesta, Raphael Bueno, Nicolas Alcala,[...]. J Thorac Oncol 2020
44
16

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
P Baas, D Fennell, K M Kerr, P E Van Schil, R L Haas, S Peters. Ann Oncol 2015
173
16

Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT).
Morihito Okada, Takashi Kijima, Keisuke Aoe, Terufumi Kato, Nobukazu Fujimoto, Kazuhiko Nakagawa, Yuichiro Takeda, Toyoaki Hida, Kuninobu Kanai, Fumio Imamura,[...]. Clin Cancer Res 2019
73
16

Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma.
Josine Quispel-Janssen, Vincent van der Noort, Jeltje F de Vries, Marion Zimmerman, Ferry Lalezari, Erik Thunnissen, Kim Monkhorst, Robert Schouten, Laurel Schunselaar, Maria Disselhorst,[...]. J Thorac Oncol 2018
96
16

Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
Jan P van Meerbeeck, Rabab Gaafar, Christian Manegold, Rob J Van Klaveren, Eric A Van Marck, Mark Vincent, Catherine Legrand, Andrew Bottomley, Channa Debruyne, Giuseppe Giaccone. J Clin Oncol 2005
432
16

Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma.
Yannis Metaxas, Gareth Rivalland, Laetitia A Mauti, Dirk Klingbiel, Steven Kao, Sabine Schmid, Anna K Nowak, Oliver Gautschi, Tammo Bartnick, Brett G Hughes,[...]. J Thorac Oncol 2018
48
16

The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy.
Gerard J Chu, Nico van Zandwijk, John E J Rasko. Front Oncol 2019
23
16

Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma.
Andreas Rimner, Marjorie G Zauderer, Daniel R Gomez, Prasad S Adusumilli, Preeti K Parhar, Abraham J Wu, Kaitlin M Woo, Ronglai Shen, Michelle S Ginsberg, Ellen D Yorke,[...]. J Clin Oncol 2016
89
16

Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.
Anne S Tsao, O Wolf Lindwasser, Alex A Adjei, Prasad S Adusumilli, Matthew L Beyers, Gideon M Blumenthal, Raphael Bueno, Bryan M Burt, Michele Carbone, Suzanne E Dahlberg,[...]. J Thorac Oncol 2018
43
16


Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.
Michele Carbone, Prasad S Adusumilli, H Richard Alexander, Paul Baas, Fabrizio Bardelli, Angela Bononi, Raphael Bueno, Emanuela Felley-Bosco, Francoise Galateau-Salle, David Jablons,[...]. CA Cancer J Clin 2019
108
16

Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
M J Byrne, J A Davidson, A W Musk, J Dewar, G van Hazel, M Buck, N H de Klerk, B W Robinson. J Clin Oncol 1999
246
16

Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.
Luana Calabrò, Aldo Morra, Ester Fonsatti, Ornella Cutaia, Carolina Fazio, Diego Annesi, Marica Lenoci, Giovanni Amato, Riccardo Danielli, Maresa Altomonte,[...]. Lancet Respir Med 2015
117
16

Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer.
Michele Carbone, J William Harbour, James Brugarolas, Angela Bononi, Ian Pagano, Anwesha Dey, Thomas Krausz, Harvey I Pass, Haining Yang, Giovanni Gaudino. Cancer Discov 2020
15
20

Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment.
Anna C Bibby, Selina Tsim, Nikolaos Kanellakis, Hannah Ball, Denis C Talbot, Kevin G Blyth, Nick A Maskell, Ioannis Psallidas. Eur Respir Rev 2016
93
16

A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations.
Sandra Pastorino, Yoshie Yoshikawa, Harvey I Pass, Mitsuru Emi, Masaki Nasu, Ian Pagano, Yasutaka Takinishi, Ryuji Yamamoto, Michael Minaai, Tomoko Hashimoto-Tamaoki,[...]. J Clin Oncol 2018
52
11

Nivo-lution in Mesothelioma.
Aaron S Mansfield, Marjorie G Zauderer. Clin Cancer Res 2019
7
28

New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma.
Marika Rossini, Paola Rizzo, Ilaria Bononi, Anthony Clementz, Roberto Ferrari, Fernanda Martini, Mauro G Tognon. Front Oncol 2018
25
11

Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy.
Raffit Hassan, Betsy Morrow, Anish Thomas, Tom Walsh, Ming K Lee, Suleyman Gulsuner, Meghana Gadiraju, Vasiliki Panou, Shaojian Gao, Idrees Mian,[...]. Proc Natl Acad Sci U S A 2019
43
11

The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification.
Francoise Galateau-Salle, Andrew Churg, Victor Roggli, William D Travis. J Thorac Oncol 2016
141
11

Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
Aurélien de Reyniès, Marie-Claude Jaurand, Annie Renier, Gabrielle Couchy, Ilir Hysi, Nabila Elarouci, Françoise Galateau-Sallé, Marie-Christine Copin, Paul Hofman, Aurélie Cazes,[...]. Clin Cancer Res 2014
74
11

Multimodal management of malignant pleural mesothelioma: where are we today?
Paul E Van Schil, Isabelle Opitz, Walter Weder, Christophe De Laet, Andreas Domen, Patrick Lauwers, Jeroen M Hendriks, Jan P Van Meerbeeck. Eur Respir J 2014
29
11

Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair.
Helen Yu, Helen Pak, Ian Hammond-Martel, Mehdi Ghram, Amélie Rodrigue, Salima Daou, Haithem Barbour, Luc Corbeil, Josée Hébert, Elliot Drobetsky,[...]. Proc Natl Acad Sci U S A 2014
197
11

High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma.
Masaki Nasu, Mitsuru Emi, Sandra Pastorino, Mika Tanji, Amy Powers, Hugh Luk, Francine Baumann, Yu-An Zhang, Adi Gazdar, Shreya Kanodia,[...]. J Thorac Oncol 2015
164
11

ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.
Arnaud Scherpereel, Isabelle Opitz, Thierry Berghmans, Ioannis Psallidas, Markus Glatzer, David Rigau, Philippe Astoul, Servet Bölükbas, Jeanette Boyd, Johan Coolen,[...]. Eur Respir J 2020
36
11

Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Fabien Forest, Arnaud Patoir, Pierre Dal Col, Abdulrazzaq Sulaiman, Florian Camy, David Laville, Sophie Bayle-Bleuez, Pierre Fournel, Cyril Habougit. Pathology 2018
21
11

CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection.
Noriyuki Yamada, Satoshi Oizumi, Eiki Kikuchi, Naofumi Shinagawa, Jun Konishi-Sakakibara, Atsushi Ishimine, Keisuke Aoe, Kenichi Gemba, Takumi Kishimoto, Toshihiko Torigoe,[...]. Cancer Immunol Immunother 2010
106
11

Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma.
Elly Marcq, Vasiliki Siozopoulou, Jorrit De Waele, Jonas van Audenaerde, Karen Zwaenepoel, Eva Santermans, Niel Hens, Patrick Pauwels, Jan P van Meerbeeck, Evelien L J Smits. Oncoimmunology 2016
35
11


A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma.
Marjorie G Zauderer, Anne S Tsao, Tao Dao, Katherine Panageas, W Victoria Lai, Andreas Rimner, Valerie W Rusch, Prasad S Adusumilli, Michelle S Ginsberg, Daniel Gomez,[...]. Clin Cancer Res 2017
22
11

Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma.
Daniel R Gomez, David S Hong, Pamela K Allen, James S Welsh, Reza J Mehran, Anne S Tsao, Zhongxing Liao, Stephen D Bilton, Ritsuko Komaki, David C Rice. J Thorac Oncol 2013
74
11

A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial.
Robert A Belderbos, Paul Baas, Rossana Berardi, Robin Cornelissen, Dean A Fennell, Jan P van Meerbeeck, Arnaud Scherpereel, Heleen Vroman, Joachim G J V Aerts. Transl Lung Cancer Res 2019
18
11

A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma.
Fausto Petrelli, Raffaele Ardito, Barbara Conti, Andrea Coinu, Mary Cabiddu, Mara Ghilardi, Karen Borgonovo, Sandro Barni, Antonio Ghidini. Respir Med 2018
11
18


CAR T-cell therapy for lung cancer and malignant pleural mesothelioma.
Masha Zeltsman, Jordan Dozier, Erin McGee, Daniel Ngai, Prasad S Adusumilli. Transl Res 2017
44
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.